Market cap
₹72 Cr
Recently Viewed
Clear AllBSE: 540204
₹50.16
₹-0.12
(-0.24%)
As on 06-May-2026IST
Market cap
₹72 Cr
Revenue (TTM)
₹46 Cr
P/E Ratio
17
P/B Ratio
1.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹4 Cr
ROE
7.8 %
ROCE
10.1 %
Industry P/E
35.71
EV/EBITDA
8.6
Debt to Equity
0
Book Value
₹44.3
EPS
₹2.9
Face value
10
Shares outstanding
14,345,854
CFO
₹-8.03 Cr
EBITDA
₹2.64 Cr
Net Profit
₹1.20 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eiko Lifesciences
| -8.9 | -0.4 | -6.1 | 2.4 | -9.0 | -5.1 | -- |
|
BSE Commodities
| 8.7 | 14.4 | 5.0 | 19.5 | 18.2 | 12.3 | 16.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Eiko Lifesciences
| -10.5 | 0.8 | 51.5 | -33.1 | 111.9 | 124.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 |
|
BSE Commodities
| 12.5 | 8.1 | 17.5 | 1.2 | 61.5 | 26.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eiko Lifesciences
|
50.2 | 72.0 | 45.6 | 4.9 | 11.9 | 7 | 17 | 1.1 |
| 497.9 | 18,033.6 | 8,302.0 | 419.0 | 8.3 | 7.1 | 43 | 3.0 | |
| 1,232.7 | 16,340.9 | 1,088.6 | 215.8 | 27.4 | 9.8 | 75.7 | 6.8 | |
| 1,360.4 | 15,495.9 | 2,229.8 | 229.1 | 18.1 | 5.7 | 90.1 | 4.8 | |
| 1,821.6 | 24,839.9 | 7,946.4 | 533.3 | 8.9 | 9.9 | 46.6 | 4.4 | |
| 4,658.8 | 14,260.7 | 2,347.3 | 398.8 | 17.9 | 16.4 | 35.9 | 5.6 | |
| 5,044.0 | 11,705.9 | 2,120.1 | 338.2 | 18.4 | 13.1 | 34.6 | 4.6 | |
| 742.1 | 11,829.0 | 4,260.9 | 265.7 | 9.0 | 9.2 | 44.6 | 3.8 | |
| 3,388.3 | 13,215.3 | 2,455.7 | 286.6 | 18.6 | 25.6 | 44 | 10.1 | |
| 1,384.7 | 14,344.7 | 2,271.4 | 442.9 | 24.7 | 15.5 | 32.4 | 4.7 |
No Review & Analysis are available.
Trusts, funds and other financial vehicles
Incorporated
1977
Chairman
Laxmikant Ramprasad Kabra
Managing Director
--
Headquarters
Thane, Maharashtra
Website
Looking for more details about Eiko Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Eiko Lifesciences Ltd is ₹50.16 (BSE) as of 06-May-2026 IST. Eiko Lifesciences Ltd has given a return of -8.96% in the last 3 years.
The P/E ratio of Eiko Lifesciences Ltd is 16.97 times as on 06-May-2026, a 52 discount to its peers’ median range of 35.71 times.
The P/B ratio of Eiko Lifesciences Ltd is 1.13 times as on 06-May-2026, a 57 discount to its peers’ median range of 2.60 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
34.20
|
1.27
|
|
2024
|
88.56
|
1.31
|
|
2023
|
71.65
|
2.16
|
|
2022
|
49.53
|
1.41
|
|
2021
|
49.25
|
4.89
|
The 52-week high and low of Eiko Lifesciences Ltd are Rs 65.90 and Rs 45.90 as of 06-May-2026.
Eiko Lifesciences Ltd has a market capitalisation of ₹ 72 Cr as on 06-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Eiko Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.